Skip to main content
. 2022 Aug 3;83:104200. doi: 10.1016/j.ebiom.2022.104200

Figure 1.

Figure 1

Epidermal growth factor receptor (EGFR) mutations in a patient with lung adenocarcinoma resistant to osimertinib. (a). EGFR mutations in a patient with lung adenocarcinoma who received chemotherapy and EGFR-tyrosine kinase inhibitor (TKI) treatment. (b). Table of mutation frequencies in tissue and circulating tumor DNA. (c). Heatmap of targeted sequencing analysis in patients with lung cancers receiving second-line osimertinib (n = 1147). (d). Structure prediction of EGFR with T790M and L792Fcis mutation in complex with osimertinib. The greenstick model shows osimertinib; the navy stick model shows the fragment of EGFR sequence from p.789 to p.798; red arrows indicate hydrogen bonds or covalent bonds linking the amino acids. CH/p interactions presented approximately 3.1 Å. Substitutions could prevent osimertinib binding by introducing spatial confliction (black arrow) from mutated residue. PR, partial response; PD, progressive disease.